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The deleterious effects of prolonged sleep deprivation on behavior and cognition are a concern in modern society.
Persons at risk for impaired performance and health-related issues resulting from prolonged sleep loss would benefit
from agents capable of reducing these detrimental effects at the time they are sleep deprived. Agents capable of
improving cognition by enhancing brain activity under normal circumstances may also have the potential to reduce the
harmful or unwanted effects of sleep deprivation. The significant prevalence of excitatory a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) glutamatergic receptors in the brain provides a basis for implementing a
class of drugs that could act to alter or remove the effects of sleep deprivation. The ampakine CX717 (Cortex
Pharmaceuticals), a positive allosteric modulator of AMPA receptors, was tested for its ability to enhance performance
of a cognitive, delayed match-to-sample task under normal circumstances in well-trained monkeys, as well as alleviate
the detrimental effects of 30–36 h of sleep deprivation. CX717 produced a dose-dependent enhancement of task
performance under normal alert testing conditions. Concomitant measures of regional cerebral metabolic rates for
glucose (CMRglc) during the task, utilizing positron emission tomography, revealed increased activity in prefrontal
cortex, dorsal striatum, and medial temporal lobe (including hippocampus) that was significantly enhanced over
normal alert conditions following administration of CX717. A single night of sleep deprivation produced severe
impairments in performance in the same monkeys, accompanied by significant alterations in task-related CMRglc in
these same brain regions. However, CX717 administered to sleep-deprived monkeys produced a striking removal of
the behavioral impairment and returned performance to above-normal levels even though animals were sleep
deprived. Consistent with this recovery, CMRglc in all but one brain region affected by sleep deprivation was also
returned to the normal alert pattern by the drug. The ampakine CX717, in addition to enhancing cognitive
performance under normal alert conditions, also proved effective in alleviating impairment of performance due to
sleep deprivation. Therefore, the ability to activate specific brain regions under normal alert conditions and alter the
deleterious effects of sleep deprivation on activity in those same regions indicate a potential role for ampakines in
sustaining performance under these types of adverse conditions.
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Introduction
The importance of a-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid (AMPA) receptors in learning and memory is
becoming increasingly more apparent [1]. Recent studies have
demonstrated that experience may directly alter GluR1
receptors in glutamatergic synaptic sites as a means by which
associative learning is manifested [2], hence agents that
modulate AMPA receptor function would provide a basis
for enhancing these same glutamatergic synaptic processes.
Ampakines are positive modulators of AMPA receptors,
which bind allosterically to GluR1–GluR4 subunits and limit
desensitization, thus provoking an increase in amplitude and/
or duration of ionic current though the glutamate-gated
channel [3–5]. Ampakines have been shown to facilitate
performance in several behavioral paradigms in rodents and
primates [6–9] and to enhance cognition in humans [10–12].
The ubiquitous distribution of AMPA receptor subtypes on
various types of neurons in nearly every brain region [13,14]
provides a feasible substrate for ampakines to enhance brain
function under normal conditions as well as in more difﬁcult
or disruptive circumstances where performance may be
compromised.
One circumstance that has been consistently shown to
interfere with the performance of complex behavioral tasks
and cognition in both humans and animal models is
prolonged sleep deprivation [15–19]. There are societal as
well as health-related reasons for counteracting the effects of
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Open access, freely available online PLoS BIOLOGYsleep deprivation such as those encountered by individuals
subjected to extended work hours or night shifts [20–23]. In
this study we employed a monkey model of cognition [24] to
examine whether ampakines would enhance task perform-
ance under normal alert conditions, as well as attenuate
demonstrated detrimental effects of 30–36 h of sleep
deprivation in the same task. We report here that the
ampakine CX717 (Cortex Pharmaceuticals) produced a
dose-dependent enhancement of performance of a delayed-
match-to-sample (DMS) task in normal alert monkeys, and
that this property extended to complete restoration of
performance impaired by sleep deprivation. To gain insight
into the neural basis for the CX717-induced positive
alterations in performance, concomitant brain imaging of
regional cerebral metabolism with positron emission tomog-
raphy (PET) was performed in the same animals. The results
revealed key brain areas engaged by the task, which under
normal alert conditions showed increased activation by
CX717. In addition, CX717 ameliorated the effects of sleep
deprivation on brain metabolic changes in most of these
regions and restored task-dependent activation patterns to
those obtained under normal alert conditions.
Results
DMS Performance and Its Facilitation by CX717
Normal alert DMS performance. The multi-image DMS task
utilized in these studies is illustrated in Figure 1 (see Materials
and Methods). Performance in the task (expressed as
percentage of correct trials) averaged 75% 6 0.3% over 11
monkeys tested under normal alert with vehicle injection
(hereafter termed ‘‘normal vehicle’’) conditions as shown in
Figure 2A. The task produced a delay-dependent decrease in
performance accuracy (F[5,1759]¼11.42, p , 0.001) as well as a
decrease associated with the number of images presented in
the match phase of the task (F[4,1759]¼19.54, p , 0.001). There
was also a signiﬁcant interaction between delay and number
of images (F[20,1759] ¼ 12.11, p , 0.001), indicating that at
longer delays, the number of images produced a more
pronounced decrease in performance (difference between
curves in Figure 2A). Variability across animals was minimal
(F[1,1759] ¼ 1.06, not signiﬁcant [NS]) and is signiﬁed by the
error bars for each mean in this and all subsequent Figures.
The inﬂuence of both the delay and number of image
parameters was also reﬂected by the change in latency to
make the match response that was independent from the
accuracy measure (percent correct). This relationship is
depicted in Figure 2B (indicated as follows: *F[1,1176] . 6.65,
p , 0.01 and **F[1,1176] . 10.88, p , 0.001) and shows that
match response latencies were inﬂuenced by number of
images and length of delay (number of images, F[4,1176]¼25.34,
p , 0.001; delay, F[5,1176] ¼ 2.61, p , 0.02). Mean match
response latency across all error trials was not signiﬁcantly
different from the shortest delay and fewest number of images
on correct trials (F[1,1176]¼1.47, NS), irrespective of trial type.
CX717 enhancement of normal alert DMS performance.
Figure 2C shows DMS performance when CX717 (0.8 mg/kg,
intravenous [IV]) was administered to normal alert animals (a
condition hereafter termed ‘‘normal þ CX717’’). CX717
markedly improved mean overall DMS performance by 15%
6 2.5% (normal vehicle, 74.9% 6 2.9% versus normal þ
CX717, 90.5% 6 1.3%; F[1,1759]¼17.49, p , 0.001) as indicated
by comparison with Figure 2A (see dashed line at 60%). The
effect of CX717 was so facilitative as to render mean perform-
ance on trials with delays of 10 s or less nearly perfect (mean
95% or greater, irrespective of number of images). On more
difﬁcult trials with delays of 21–30 s and ﬁve or six images, the
Figure 1. Multi-Image Visual DMS Task
DMS trials consist of four phases. In the first, the start-trial phase, a circle was displayed to initiate the trial. The monkey had to move the cursor into the
circle to initiate presentation of the sample image. Next, in the sample phase, a single ‘‘sample’’ clip art image (red star) was presented. Movement of
the cursor into the sample image blanked the screen and initiated the delay phase. In this third phase, delay, the screen was blanked for a 1–30 s
interval (randomly selected on each trial); the match phase was initiated automatically at the end of delay phase. In the last, match phase, the sample
image was presented simultaneously with one to five other randomly chosen ‘‘nonmatch’’ images. Images could appear randomly at any of nine
spatially distinct screen locations. The sample image always appeared at a different location in the match phase, and monkeys were required to place
the cursor in the sample image for 200 ms or longer to be rewarded and terminate the trial. Movement of cursor into a nonmatch image for 200 ms or
longer terminated the trial with no reward. Each clip-art image (including samples and nonmatches) was selected from a list of 5,000 clip art images and
presented only once, such that all trials were unique with no repetition of images during the session. The intertrial interval was 10 s, in which the screen
was blank prior to the appearance of the start-trial circle.
DOI: 10.1371/journal.pbio.0030299g001
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Ampakines Combat the Effects of Sleep Deprivationoverall mean increase of 25% in performance in the normalþ
CX717 condition relative to normal vehicle condition was also
highly signiﬁcant (mean normal vehicle, 46.7% 6 4.8% versus
mean normal þ CX717, 71.7% 6 2.4%; F[1,1759] ¼ 26.46, p ,
0.001). Figure 2D shows markedly decreased match response
latencies at all delays and #image trial types relative to the
normal vehicle condition (overall F[1,1176] ¼ 14.70, p , 0.001;
speciﬁc comparisons with normal vehicle indicated in Figure
2D as follows:
þF[1,1176] . 7.77, p , 0.01and
þþF[1,1176] . 12.55, p
, 0.001), but the trend for increased latencies as a function of
longer delays and increased number of images was not
eliminated by CX717 (F[20,1176] ¼ 4.21, p , 0.01). Mean start-
trial and mean sample response latencies (see Figure 1) were
also signiﬁcantly reduced from normal vehicle sessions (start-
trial, F[1,1176] ¼ 15.23, p , 0.001; sample, F[1,1176] ¼ 18.46, p ,
0.001); however, these latencies were not sensitive to trial type.
Dose-Related Facilitation of DMS Performance by CX717
Figure 3A shows the dose-dependent facilitation of DMS
performance by CX717 in nine monkeys in individual normal
þ CX717 sessions (dose range, 0.3–1.5 mg/kg). Daily sessions
employing different doses were interleaved with vehicle
sessions and showed consistency across monkeys with respect
to degree of facilitation. Daily performance on vehicle
sessions ranged between 70%–84% correct trials, while
performance on the individual interleaved drug sessions
ranged between 81%–98% correct (Figure 3A; ‘‘C’’on x-axis
and arrow denote drug day). The dose of 1.5 mg/kg produced
a mean overall increase of 15.1% 6 0.3% (F[1,1759]¼12.98, p ,
0.001) and the 0.8 mg/kg dose a mean overall increase of
12.2% 6 0.5% (F[1,1759] ¼ 7.02, p , 0.01), while doses of 0.5
mg/kg or less were not as efﬁcacious (mean increase, 6.1% 6
0.2%, F[1,1759] ¼ 3.53, NS). The onset and selectivity of the
facilitative effects of CX717 on DMS performance were
further demonstrated in four animals for which CX717 (0.8
mg/kg) was not administered until halfway through the
session (split-session, Figure 3B). Performance improved by
12.8% 6 0.5% (F[1,1759] . 13.91, p , 0.001) during the second
versus the ﬁrst half of the session. The overall means for the
three different doses of CX717 across all animals tested (n¼9)
are shown in Figure 3C. Response latencies for start-trial,
Figure 2. DMS Performance and Match Response Latency under Normal Vehicle and Normal þ CX717 Conditions
(A) Normal vehicle condition, mean (6 SEM) percent correct DMS performance across 11 monkeys. Each curve reflects percent correct DMS trials sorted
by number of images (two to six) in the match phase on trials with different delays (1–30 s plotted in 5-s increments). Performance decreased both as a
function of delay and number of images as indicated by separation of curves across delays. ‘‘C’’ on y-axis indicates random or ‘‘chance’’ performance
level in task. Asterisks indicate degree of separation from 1–5 s delay trials for significant (*p , 0.01, **p , 0.001) differences, and daggers indicate
minimum degree of separation for significance (
p , 0.01,
p , 0.001) compared to two-image trials.
(B) Match phase response latencies in s (mean 6 SEM) for trials shown in (A). Latencies on correct trials were sorted and plotted by number of images at
specified delays. Asterisks indicate significant differences (*p , 0.01, **p , 0.001) compared to the mean of two-image trials summed across all delays
(dashed line).
(C) NormalþCX717 condition; mean (6 SEM) percent correct performance by the same animals as in (A) following administration of CX717 (0.8 mg/kg,
IV) prior to start of session. Legend is the same as in (A) for number of images and duration of delay. Performance across both parameters was
maximally facilitated as indicated by comparison to dashed line arbitrarily drawn at 60%. Daggers indicate significant difference compared to two-
image trials (
p , 0.01,
p , 0.001). Plus signs indicate significant mean differences (
þp , 0.01,
þþp , 0.001) compared to the respective number of
images in normal vehicle condition.
(D) Match response latencies in s (mean 6 SEM) for normalþCX717 condition sorted by delay and number of images as in (B). Dashed line provides a
basis for comparison with minimum latency (1.5 s) in normal vehicle condition (B). Asterisks indicate significant differences (*p , 0.01, **p , 0.001) at all
delays compared to two-image trials. Plus signs indicate significant differences (
þp , 0.01,
þþp , 0.001) compared to the same trial type in normal
vehicle condition (B).
DOI: 10.1371/journal.pbio.0030299g002
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manner (all F[2,1176] . 10.30, p , 0.001).
Effects of Sleep Deprivation on DMS Performance and
Restoration by CX717
Effects of sleep deprivation on DMS performance. Figure
4A shows that 30–36 h of sleep deprivation (with vehicle;
hereafter termed ‘‘sleep deprivation’’) signiﬁcantly reduced
overall DMS performance from the normal vehicle condition
(mean performance with sleep deprivation, 62.7% 6 2.5%,
F[1,1759]¼15.42, p , 0.001). The effects of sleep deprivation on
performance were not differential with respect to delay, since
there was a major deﬁcit in performance (10.3% overall
decrease) on long-delay trials with increased number of
images (21–30 s with ﬁve and six images: mean normal
vehicle, 46.7% 6 3.0% versus mean sleep deprivation, 36.4%
6 1.9%; F[1,1759]¼8.62, p , 0.01) and a marked 9.1% decrease
on trials with the shortest (1–10 s) delays and the fewest (two
and three) number of images (mean normal vehicle, 95.8% 6
1.1% versus mean sleep deprivation, 86.7% 6 3.0%; F[1,1759]¼
8.33, p , 0.01; compare with dotted line in Figure 2A). This
was also reﬂected by the signiﬁcant overall proportionate
change (118% 6 6%) in the match response latency
distribution (Figure 4B) with no differential effect on any
one trial type. Although not signiﬁcant for two images, sleep
deprivation increased latencies systematically at three to six
images, showing a similar interaction with delay as in the
normal vehicle condition (see Figure 2B) but to a much
greater extent (overall, F[1,1176]¼17.45, p , 0.001; comparison
with normal vehicle condition indicated on Figure 2B as
follows:
þF[1,1176] . 7.17, p , 0.01;
þþF[1,1176] . 10.28, p ,
0.001). Signiﬁcant increases in mean latency were also
exhibited in the start-trial and sample response latencies
(see Figure 1) of the task (start-trial, F[1,1176] ¼ 11.46, p ,
0.001; sample, F[1,1176] ¼ 13.91, p , 0.001); however, they did
not increase systematically with trial type.
Figure 3. Effects of Different Doses of CX717 on DMS Performance in Normal þ CX717 Condition
(A) CX717 is shown administered on consecutive sessions for nine monkeys over three dose ranges of CX717 (0.3–0.5 mg/kg, 0.8–1.0 mg/kg, and 1.5
mg/kg, IV). Each CX717 session (C, arrows) was interspersed with a single normal vehicle (V) session. Curves show mean (6 SEM) percent correct
performance over the entire session from each different monkey, as indicated by separate symbols. Arrows indicate CX717 sessions (also denoted by
‘‘C’’ on axis). Note escalating doses (0.3, 0.8, and 1.5 mg/kg) shown were in four of the nine monkeys.
(B) Performance on split sessions (n¼4 monkeys) in which vehicle was administered at the start of the DMS session, and midway through same session
CX717 (0.8 mg/kg, IV) was administered via remote pump without interruption. Mean (6 SEM) percent correct performance over at least 50 trials was
calculated separately for the first half (vehicle) and second half (CX717, 0.8 mg/kg) of the same session. Asterisks indicate a significant (** p , 0.001)
increase in the second half of the session relative to the first (vehicle).
(C) Overall mean dose-effect relationship of CX717 on normal alert DMS performance across monkeys (n ¼ 9) in sessions in which each of the three
doses (0.3, 0.8, and 1.5 mg/kg, IV) was administered. DMS sessions in which the three doses were received in an escalating order were compared with
sessions in which the same doses were administered in a randomized order (F[1,50]¼2.31, p¼13.5, NS). Asterisks indicate significant (*p , 0.01, **p ,
0.001) difference relative to vehicle sessions.
DOI: 10.1371/journal.pbio.0030299g003
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Ampakines Combat the Effects of Sleep DeprivationEffects of CX717 on DMS performance in sleep-deprived
animals. When CX717 (0.8 mg/kg IV) was administered 10 min
prior to testing animals that were 30–36 h sleep deprived
(hereafter termed ‘‘sleep deprivation þ CX717’’), the detri-
mental effects on DMS performance were eliminated. Figure
4C shows that DMS performance in sleep-deprived animals
was markedly improved (mean sleep deprivation þ CX717,
84.5% 6 2.0% versus mean sleep deprivation, 62.7% 6 2.5%;
F[1,1759] ¼ 21.71, p , 0.001) and in fact, was signiﬁcantly
elevated relative to the normal vehicle condition (compare
with dotted line in Figure 2A) as indicated by a overall mean
increase of 9.6% 6 2.5% (F[1,1759] ¼ 9.43, p , 0.001). This
reversal by CX717 was characterized by a marked shift to
shorter match response latencies relative to the sleep
deprivation condition (indicated on Figure 4D as follows:
#F[1,1176] . 8.50, p , 0.01,
##F[1,1176] . 11.14, p , 0.001) and by
smaller differences in match response latency between trial
types within the sleep deprivationþCX717 condition (F[1,1759]
¼ 7.86, p , 0.01). In addition, match response latencies were
signiﬁcantly shorter (indicated on Figure 4D as follows:
þF[1,1176] . 6.78, p , 0.01;
þþF[1,1176] . 10.74, p , 0.001) than
in the normal vehicle condition (dotted line in Figure 4D).
The changes in performance produced in sleep-deprived
monkeys receiving CX717 were also reﬂected as decreased
response latencies in the other phases of the task (start-trial,
F[1,1176]¼15.58, p , 0.001; sample, F[1,1176]¼12.81, p , 0.001;
match, F[1,1176] ¼ 17.25, p , 0.001 versus sleep deprivation),
but again, not associated with trial type.
Effects of Sleep Deprivation and CX717: Delay and
Number of Images
Figure 5 summarizes the effects of all four testing
conditions collapsed across the two main DMS task param-
eters of delay (Figure 5A) and number of images (Figure 5B).
It is clear that both parameters controlled performance in all
four test conditions in the same manner, with performance
decreasing as a function of both duration of delay (overall
effect of delay, F[5,1759] ¼ 10.44, p , 0.001; Figure 5A) and
number of images (overall effect of number of images, F[4,1759]
¼ 6.49, p , 0.001; Figure 5B). Administration of CX717 (0.8
mg/kg IV, squares) markedly improved performance relative
to normal vehicle sessions with respect to both parameters
(delay, F[5,1759] . 12.21, p , 0.001; number of images, F[4,1759]
. 15.22, p , 0.001; Figure 5, squares), while sleep deprivation
produced signiﬁcant impairment with respect to these two
task parameters (Figure 5, triangles). Administration of
CX717 (0.8 mg/kg IV) not only reversed performance deﬁcits
in the sleep deprivation condition, but also increased levels
Figure 4. Effects of Sleep Deprivation and Sleep Deprivation þ CX717
(A) Sleep deprivation condition disrupts DMS performance. Mean percent correct performance across animals for sessions following 30–36 h of sleep
deprivation (nine of 11 monkeys in Figure 2A). Plus signs indicate significant mean differences (
þp , 0.01,
þþp , 0.001) compared to the respective
number of images curve in the normal vehicle condition; dashed line at 60% allows comparison with Figure 2A.
(B) Match response latencies in s (mean 6 SEM) sorted for different trial types as in Figure 2B. Asterisks indicate significant difference (*p , 0.01, **p ,
0.001) at all delays compared to two-image trials. Plus signs indicate significant differences (
þp , 0.01,
þþp , 0.001) compared to same trial types, and
dashed line allows comparison with minimum latencies in normal vehicle condition (Figure 2B).
(C) Sleep deprivation þ CX717 condition. Effects of administration of CX717 (0.8 mg/kg, IV) 10 min prior to DMS session following 30–36 h of sleep
deprivation. Mean (6 SEM) percent correct DMS trials for same delay (1–30 sec, in 5-s increments) and #image (two to six) DMS conditions generated by
same monkeys tested in (A). Plus signs indicate significant mean differences (
þp , 0.01,
þþp , 0.001) compared to the respective number of images
curve in the normal vehicle condition (Figure 2A); pound signs (
#p , 0.01,
##p , 0.001) indicate significant differences compared to the same trial types
in sleep deprivation condition. Dashed reference line allows comparison with sleep deprivation (A) and normal vehicle conditions (Figure 2A).
(D) Match response latencies for same sleep deprivation þ CX717 condition shown in (C), sorted by delay and number of images and labeled as in
Figure 2B. Pound signs (
#p , 0.01,
##p , 0.001) indicate significant differences compared to the same trial types in sleep deprivation condition (A).
DOI: 10.1371/journal.pbio.0030299g004
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parameters commencing at delays of more than 10 s
(compare diamonds and circles in Figure 5 at points
indicated by asterisks; delay, F[5,1759] ¼ 9.64, p , 0.001;
number of images, F[4,1759] ¼ 10.20, p , 0.001).
Electroencephalogram Correlates of Sleep and Effects of
CX717
Surface electroencephalogram (EEG) was recorded during
DMS testing in four animals utilizing a conﬁguration of
electrodes inserted through a craniotomy access cylinder
positioned over the parietal cortex. Power spectral density
(PSD) analyses were calculated from the EEG sequentially in
4.0s epochs and averaged over 10-min segments for statistical
comparisons. Mean PSD graphs shown in Figure 6 (upper
graphs) reveal marked changes in the EEG characteristic of
sleep deprivation relative to the normal vehicle condition
including (1) a speciﬁc increase in power of the ‘‘delta’’ (0.5–5
Hz) band reported to be associated with slow-wave sleep [25–
27], and (2) peaks in the ‘‘beta’’ band (18–25 Hz) reported to
increase during REM sleep [28,29]. Across all four animals,
these two changes were signiﬁcantly correlated with de-
creased accuracy of performance in the same testing sessions
(percent correct, r
2¼0.72, F[1,128]¼9.94, p , 0.01; Figure 4A).
Individual frequency shifts in the EEG, as indicated by the
lower traces in Figure 6, were assessed by PSD analyses in 4.0 s
epochs across the entire session and showed marked
elevations in the number of transient incidences in which
power in the delta and beta bands increased in sleep-deprived
animals. Such changes have been reported to reﬂect
occurrences of ‘‘microsleep’’ episodes [30,31]. In the sleep
deprivation þ CX717 condition there was a distinct shift
toward the normal vehicle proﬁle of EEG and PSD traces
(Figure 6, right) characterized by a marked reduction of
power (F[2,61] ¼ 6.17, p , 0.01) in the beta band and slower
delta frequencies (Figure 6, right).
Rates of Local Cerebral Metabolism during Task
Performance
Statistical parametric maps using SPM99 software were
generated for comparisons of relative cerebral metabolic
rates for glucose (CMRglc) across nine monkeys (Figure 7).
When compared to the ‘‘neutral’’ baseline scan condition
consisting of a video viewed in lighting and audio conditions
identical to task conditions with no arm movements required,
relative CMRglc during the DMS task was increased in the
premotor, motor, and somatosensory cortices of the left
hemisphere as shown in Figure 7A, 7B, and 7D (horizontal
and coronal views). These asymmetric activations reﬂect the
use of the contralateral (right) arm and hand to perform the
DMS task versus the baseline condition, and as such provide a
validation of CMRglc as an accurate indicator of functional
neuronal activity expressed within speciﬁc brain regions
during the task. Further veriﬁcation was provided by
increased bilateral activation detected in the cortical frontal
eye ﬁelds (Figure 7A and 7B) relative to baseline, reﬂecting
extensive eye movements during visual scanning required by
the task (see Figure 1).
CMRglc during DMS task performance. Planned compar-
isons of relative CMRglc in each of the four test conditions
were made in ﬁve regions of interest (ROIs): the bilateral
dorsal prefrontal cortex (DPFC), dorsal striatum (DStr), and
medial temporal lobe (MTL), as well as the thalamus and
precuneate cortex. Performance of the DMS task, when
compared to the baseline condition, signiﬁcantly increased
CMRglc bilaterally in DPFC (left, tdiff [paired comparisons
hereafter referred to as t]¼3.65, p , 0.012; right, t¼3.75, p ,
0.007) as can be seen in Figure 7C and within the MTL (Figure
7D), which included the hippocampus and surrounding
medial temporal cortex (left hemisphere, t ¼ 2.68, p , 0.02;
right, t¼3.86, p , 0.02). Signiﬁcant activation was also seen in
the left DStr (t ¼ 2.77, p , 0.02). No signiﬁcant changes were
observed in the thalamus or precuneate portion of the
parietal cortex (Figure 7E).
Effects of CX717 on CMRglc. CMRglc in the normalþCX717
(0.8 mg/kg, IV) condition was signiﬁcantly elevated in DPFC
Figure 5. Separation of Effects of Sleep Deprivation þ CX717 on DMS
Performance Parameters, Delay Versus Number of Images
(A) Mean (6 SEM) percent correct performance across animals on DMS
trials sorted by delay (1–30 sec, in 5 s increments) and summed over two
to six image trials for normal vehicle, normalþCX717, sleep deprivation,
and sleep deprivationþCX717 conditions (separate curves). Data are the
same as shown in Figures 2 and 4.
(B) Mean (6 SEM) percent correct performance for DMS trials partitioned
by number of images and summed over 1–30 s delays for the same four
treatment conditions shown in (A).
Asterisks indicate separation limits for significant differences (*p , 0.01,
**p , 0.001) of CX717 and sleep deprivation means compared to the
normal vehicle mean; § symbol indicates that all points on the indicated
curve differ significantly from all points on normal vehicle curve.
DOI: 10.1371/journal.pbio.0030299g005
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Ampakines Combat the Effects of Sleep DeprivationFigure 6. EEG and PSD Measures in Sleep-Deprived Monkeys
Measures superimposed (n¼4) are average PSD (upper graphs) and individual sample EEGs (lower tracings), recorded from electrodes placed over the
parietal cortex, shown for three different treatment conditions (left, normal vehicle; middle, sleep deprivation; and right, sleep deprivation þ CX717).
In the graphs (upper) are shown PSDs for EEGs recorded from animals performing the DMS task. Sleep deprivation condition (middle) shows increased
power of high-amplitude, slow-wave delta band (0.5–5 Hz, above dotted line) and two prominent peaks in the beta band (18–25 Hz) at 20 and 25 Hz
(asterisks) relative to the normal vehicle condition (left). Reduction of sleep deprivation features of PSD in same animals following administration of
CX717 (0.8 mg/kg) is indicated at right by a decrease in PSD delta band (0.5–5 Hz, dotted line) and reduction in power of peaks (asterisks) in the beta
band (18–25 Hz). PSDs were calculated as log of root-mean-square power in 10-min segments of EEG recordings, using frequency increments of 0.25 Hz,
plotted separately for four monkeys in each condition (individual traces).
In the tracings (lower) are shown EEG segments (4.0 s) recorded from one of five electrode locations on the surface of the parietal cortex to demonstrate
different EEG frequencies present in each condition. Traces correspond to the respective DMS testing sessions shown in the PSD plots above.
DOI: 10.1371/journal.pbio.0030299g006
Figure 7. SPM Maps of Brain Regions Showing Changes in Regional CMRglc during Performance of DMS Task for Normal Vehicle and NormalþCX717
Conditions
(A–E) Maps are shown for the comparison of CMRglc during DMS performance in the normal vehicle to the baseline, no-task condition. CMRglc was
significantly increased during normal vehicle condition compared to baseline, no-task condition.
(F–H) Maps are shown for the comparison of CMRglc during DMS performance in the normalþCX717 condition to normal vehicle condition. CMRglc was
increased following the administration of CX717 (0.8 mg/kg, IV) as compared to normal vehicle condition (C–E).
Regional changes are displayed on both horizontal section (A) and coronal sections (B–H) of MR images of rhesus monkey brain at the level of the
motor and premotor cortex (A and B), DPFC (C and F), MTL (D and G), and parietal cortex (E and H). Statistical parametric maps were generated using
SPM99 software. Colors indicate the location of clusters with a height (magnitude) threshold of p , 0.05 and spatial extent greater than 50 voxels. Color
bar indicates t values for the comparisons (red, t¼2.0, p , 0.05; yellow, t¼5.0, p , 0.001). Note: left and right half of hemisphere are shown on left and
right of images respectively. Area 6, premotor cortex; Cere, cerebellum; FEF, frontal eye fields; Prec, precuneus; S1, primary somatosensory cortex.
DOI: 10.1371/journal.pbio.0030299g007
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in MTL (Figure 7G; left, t ¼ 3.06, p , 0.02; right, t ¼ 3.67, p ,
0.01) relative to the normal vehicle condition. The most
prominent effect, however, was seen in the precuneus, where
CMRglc (which was not signiﬁcantly altered by the task when
compared to the baseline condition [Figure 7H]) was
markedly increased by CX717 compared to the normal
vehicle condition (t¼4.10; p , 0.003). There were no further
increases in CMRglc in the DStr or thalamus in the normal þ
CX717 condition.
Effects of sleep deprivation on CMRglc. Sleep deprivation
produced both increases and decreases in relative CMRglc
(Figure 8A–8C) throughout the ROIs activated in either the
normal vehicle and/or normal þ CX717 conditions. Compar-
ing the sleep deprivation condition to the DMS task condition
revealed marked increases in CMRglc in the MTL (Figure 8C;
left, t ¼ 4.36, p , 0.003; right, t ¼ 4.09, p , 0.006), as well as
within the precuneus (t¼4.06, p , 0.006). In contrast, Figure
8A shows that CMRglc was signiﬁcantly decreased bilaterally in
the DPFC (left, t¼3.33, p , 0.01; right, t¼3.72, p , 0.009), and
in the left DStr (Figure 8B; t ¼ 3.28, p , 0.02). The thalamus,
which was not changed from the no-task baseline in either the
normal vehicle or normalþCX717 conditions, showed a very
large decrease in CMRglc (t ¼ 3.97, p , 0.007) during
performance of the task in the sleep deprivation condition.
Effects of sleep deprivation and CX717 on CMRglc. The
administration of CX717 (0.8 mg/kg IV) to sleep-deprived
monkeys during the DMS task produced signiﬁcant changes
in CMRglc (Figure 8D–8F) in all but one of the brain regions
affected by sleep deprivation. CMRglc in the DPFC (Figure 8D)
was elevated bilaterally in the sleep deprivation þ CX717
compared to the sleep deprivation condition (left, t ¼ 3.87, p
, 0.003; right, t ¼ 3.43, p , 0.007). Similar increases were
found bilaterally in the DStr (Figure 8E; left, t ¼ 6.24, p ,
0.001; right, t ¼ 6.34, p , 0.004). Thus, CMRglc in the DPFC
and DStr, although decreased in the sleep deprivation
Figure 8. SPM Maps of Brain Regions Showing Changes in Regional CMRglc During Performance of DMS Task for Sleep Deprivation and Sleep
Deprivation þ CX717 Conditions
(A–C) Maps are shown for the comparison of CMRglc during DMS performance in sleep deprivation to normal vehicle conditions (see Figure 7C–7E).
Decreases (blue) are shown for DPFC (A), DStr (B), and thalamus (Thal; C). Increases in CMRglc (orange and yellow) are shown in C for MTL.
(D–F) Maps shown for comparison of CMRglc during DMS performance in sleep deprivationþCX717 (0.8 mg/kg, IV) to the sleep deprivation condition.
Increases in CMRglc were observed in DPFC (D) and DStr (E), whereas decreases were observed in MTL (F). Absence of labeled voxels for thalamus (Thal)
in (F) indicates no change from sleep deprivation (C above) versus sleep deprivation þ CX717 conditions.
Regional changes are displayed on coronal sections of MR images of rhesus monkey brain at the level of the DPFC (A,D), DStr (B,E) and MTL (C,F).
Statistical parametric maps were generated using SPM99 software. Colors indicate the location of clusters with a height threshold of p , 0.05 and
spatial extent greater than 50 voxels. Color bars indicate t values (2–5; corresponding to p , 0.05 to p , 0.001, respectively) for significance of increase
(red-yellow) or decrease (blue-green) in comparisons. Left and right hemispheres are on the left and right of images respectively.
DOI: 10.1371/journal.pbio.0030299g008
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conditions following CX717 administration. In contrast,
signiﬁcant decreases in CMRglc were observed in the MTL
(Figure 8F; left, t ¼ 4.34, p , 0.007; right, t ¼ 7.85, p , 0.001)
and precuneus (t¼4.85; p , 0.002) in the sleep deprivationþ
CX717 condition, which constituted a directional change
from the elevated level in the sleep deprivation condition.
Unexpectedly, CX717 did not have a signiﬁcant effect in the
thalamus, where CMRglc remained severely depressed as in
the sleep-deprivation condition.
To assess whether the depressed CMRglc in the DPFC and
DStr and the increased CMRglc in the MTL and precuneate
regions produced by CX717 administration in sleep-deprived
animals was, in effect, a shift toward normal vehicle levels, the
sleep deprivation þ CX717 condition and normal vehicle
conditions were compared directly. This comparison showed
no signiﬁcant differences in CMRglc in the DPFC, DStr, or
MTL. In other words, there were no voxels within these ROIs
that met the cluster threshold of p , 0.05, indicating a lack of
difference between the two conditions for these regions.
However, in this same comparison, CMRglc in the thalamus
remained signiﬁcantly decreased (t ¼ 5.32, p , 0.001).
Multivariate Analyses of CX717 and Sleep Deprivation
Effects
While the above analyses of behavioral performance (see
Figures 2–5) and measures of CMRglc (see Figures 7 and 8)
demonstrated overall mean effects of CX717 and/or sleep
deprivation summed across animals, a multivariate canonical
discriminant analysis (CDA [32]) demonstrated conclusively
that these measures actually covaried within individual
animals across the four test conditions. The CDA identiﬁed
and extracted orthogonal sources of variance between
animals and treatment conditions that derived from six
different measures of DMS task performance and CMRglc
values from six different brain regions in the same animals
(see Materials and Methods). The extracted discriminant
functions (DFs) are shown in Figure 9A as mean DF scores
averaged across animals (mean 6 standard error of the mean
[SEM]). Each of the three DFs is plotted relative to its mean
value in the normal vehicle condition (Figure 9A; ‘‘0’’ line in
graph) for each of the other three test conditions (normal þ
CX717, sleep deprivation, and sleep deprivation þ CX717).
The three discriminant functions shown in Figure 9A (DFs
1, 2, and 3) accounted for 94% of total variance in the
covariance matrix. The largest, DF1 (54% of total variance,
F[11,612] ¼ 32.40, p , 0.001, relative to residual variance, red
curve), was maximally positive when performance was
signiﬁcantly improved in the normal þ CX717 condition,
maximally negative when performance was severely impaired
in the sleep deprivation condition, and returned to positive in
the sleep deprivation þ CX717 condition. The second largest
source of variance, DF2 (24% of total variance, F[11,612]¼13.79,
p , 0.001, green curve), was signiﬁcantly positive (relative to
its value in the normal vehicle condition) whenever CX717 was
administered independent of whether animals were alert or
sleep deprived (i.e., normal þ CX717, sleep deprivation þ
CX717). The third signiﬁcant source of variance, DF3 (14% of
total variance, F[11,612]¼11.45, p , 0.001, blue curve), differed
from the normal vehicle condition during the two sleep
deprivation conditions, indicated by negative scores, irre-
spective of whether CX717 was administered.
A subset of the CDA covariance matrix examined CMRglc
measures for each of six selected brain regions (see Materials
and Methods) with respect to the same three DFs shown in
Figure 9A. Each bar in Figure 9B shows the mean (6 SEM)
discriminant score for increases (positive) and decreases
(negative) in CMRglc in each of the three test conditions
relative to the normal vehicle condition. The colored
segments of each bar reﬂect the proportionate degree of
variance in CMRglc level associated with the three DFs shown
in Figure 9A within a given region (same color code). It is
clear from Figure 9B that DF2 (CX717, green segments) and
DF3 (sleep deprivation, blue segments) had large inﬂuences
on regional CMRglc and tended to vary inversely across the
three test conditions. CMRglc values in MTL, parietal cortex
(precuneate), DStr, and DPFC were differentially inﬂuenced
by DF2 and DF3 in relation to their values in the normal
vehicle condition (‘‘0’’ in Figure 9B). The large extracted
variances associated with these regions resulted from (1)
changes produced by sleep deprivation (see Figure 7E) and (2)
the corresponding reversal of those effects in the sleep
deprivation þ CX717 condition (see Figure 8). Consistent
with the above ﬁndings, the thalamus was inﬂuenced
exclusively by DF3, the factor associated with sleep depriva-
tion (blue segments in Figure 9B), showing intense reductions
in CMRglc levels in both sleep deprivation test conditions
regardless of the presence of CX717.
Discussion
The AMPA receptor modulator CX717, given to monkeys
engaged in cognitive processing and short-term memory,
improved performance in all aspects of the DMS task (see
Figures 2 and 5). This enhanced performance was evidenced
by signiﬁcant increases in accuracy at all delays and number
of images (see Figure 5) and was paralleled by reductions in
latency to select the correct image during the match phase of
the task (see Figure 2). In addition to the effects on normal
alert performance, the present ﬁndings also demonstrated
that CX717 removed severe performance deﬁcits produced
by subjecting the animals to prolonged periods of sleep
deprivation (see Figure 4). In conjunction with the effects on
behavioral performance, CX717 also affected CMRglc in brain
regions engaged while performing the task under normal and/
or sleep deprived conditions (see Figures 7 and 8). The results
show a strong functional relationship between the neuro-
biological and behavioral effects of the drug and provide
insight into how performance in this cognitive task is
facilitated by ampakines.
Reportsfromthisandotherlaboratorieshavedemonstrated
enhanced performance by other AMPA receptor modulators
under normal alert conditions [6–9], one of which employed a
task with monkeys similar to the one utilized here [9]. The
current ﬁndings extend the basis for the facilitative actions of
ampakines to the parallel yet equally sensitive measure, match
response latency (see Figures 2B, 2D, 4B, and 4D). The
signiﬁcant modulation of match response latencies by task
parameters in the same manner as performance accuracy
(percent correct trials) suggests that CX717 also facilitated
attentional processes [33] related to speed of responding on
successful trials (Figure 7A and 7B), even if the animals were
sleep deprived (see Figure 4D). Since this measure was
markedly facilitated by CX717 under normal alert conditions
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speed of detection of the correct match target.
The marked inﬂuence of sleep deprivation on performance
(see Figures 4 and 5) was paralleled by signiﬁcant alterations
in CMRglc in DPFC, DStr, precuneate cortex, and MTL (Figure
8), demonstrating the contribution of a sleep-related factor to
brain regions engaged by the DMS task (DF3 in Figure 9). It is
also evident that both behavioral and brain metabolic
processes sensitive to sleep deprivation were affected by
administration of CX717 (see Figures 8 and 9). Although it is
possible that the positive effect of CX717 in sleep-deprived
animals was due to an increase in arousal, this explanation is
unlikely because of the potent dose-dependent action of the
drug in normal animals (see Figure 2B, Figure 5). The
performance levels of animals in the sleep deprivation
condition were reduced signiﬁcantly compared to normal
vehicle sessions; however, a close examination of latencies (see
Figures 4 and 5) shows that animals continued to respond in
the match phase in a rapid manner (2.5–3.0 sec). The
assessment of EEG parameters, although not designed to
provide a thorough analysis of sleep architecture, suggests that
animals were experiencing microsleep episodes during the
sleep deprivation testing condition [30,31]. However, these
instances did not signiﬁcantly alter the mean number of trials
completed during sessions that were the same duration as
normal vehicle tests, nor was the latency to respond to events
during the trial elevated more than 1–2 s above normal vehicle
sessions (see Figures 4 and 9). While preliminary analyses
showed that administration of CX717 reduced the incidences
of delta and beta band occurrences in sleep-deprived animals
(see Figure 6), more rigorous assessments of EEG-related
changes in the sleep states of the animals will be required to
reveal the exact means by which this reversal occurred.
The MTL (including hippocampus) and DPFC have been
extensively implicated in both working and short-term
memory in monkeys and humans [34–37]. The differential
Figure 9. Multivariate CDA of DMS Performance and Brain CMRglc Activity
(A) Discriminant functions (DFs 1, 2, and 3) were extracted via CDA from covariance matrices for 12 dependent variables of DMS performance and
CMRglc for nine monkeys across the four treatment conditions (see Materials and Methods). Discriminant scores for each DF (different colored curves)
were computed for each animal and treatment condition. Scores were rotated via the CDA for orthogonality, and then standardized with mean of zero,
standard deviation 6 1.0, relative to the normal vehicle condition for comparison to the other three test conditions and plotted as means (6 SEM)
across all animals. Positive mean scores for DF1 indicate increased accuracy (i.e., percent correct trials) and decreased latency in DMS performance, while
negative scores indicate decreased accuracy and increased latency. Note that scores for DF2 increased when DF1 increased. Scores for DF3 show only
decreases associated with both sleep deprivation conditions. Asterisks indicate significant (*p , 0.01, **p , 0.001) difference compared to normal
vehicle score for the respective DF.
(B) A component of the CDA analysis extracted sources of variance associated with changes in absolute CMRglc (see Materials and Methods) across the
six ROIs described in Figures 7 and 8. The length of each bar reflects the total change in CMRglc measured in that structure (i.e., the ROI). Positive scores
indicate relative increases in CMRglc within a brain region with respect to their levels in the normal vehicle condition (‘‘0’’). Negative scores indicate
relative decreases in CMRglc within a brain region. Each colored segment of the bar indicates the proportion of total CMRglc variance contributed by
each of the respective DFs (A) for a given treatment condition: DF1 (orange), DF2 (green), DF3 (blue). Asterisks indicate conditions with significant( * p ,
0.01, **p , 0.001) differences in CMRglc compared to normal vehicle. Height of small black bars at right indicate significance levels for colored segments
of bars.
DOI: 10.1371/journal.pbio.0030299g009
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candidates for the functional substrates of the type(s) of
memory process required to successfully perform this DMS
task [24,38]. Further evidence suggests that the activation of
DPFC and MTL reﬂected utilization of generalized encoding
principles shown also in humans [39]. Although there also
exist differences in humans with respect to tasks that are
susceptible to sleep deprivation [40], the fact that perform-
ance of this task was severely disrupted, and that both the
DPFC and MTL were affected, are consistent with studies in
humans showing that repetitive working memory tasks that
require a high degree of vigilance are affected by sleep
deprivation in a similar manner [41]. In addition, Benca et al
[26] showed that 24-h sleep architecture was drastically
altered in monkeys sustaining lesions of the amygdala, an
area possibly contributing to the changes in CMRglc in the
MTL in the current ﬁndings.
The detrimental effects on DMS performance of 30–36 h of
sleep deprivation in monkeys reported here (see Figures 4A
and 5) are difﬁcult to compare directly with different
durations of sleep deprivation in humans [16,42]. Given the
severity and magnitude of the deﬁcit, it is possible that this
degree of sleep deprivation in monkeys has more of an effect
than in humans more adapted to a 30–36 h (a single night)
sleep deprivation period. The current ﬁndings are consistent
with some reports in humans that show extensive sleep-
deprivation-produced deﬁcits in prefrontal-cortex-sensitive
cognitive tasks [15,27,42]. However, other reports suggest that
complete resolution of these issues will require conﬁrmation
that the DMS task employed here is similar to the verbal and/
or arithmetic tests used to dissociate different brain regions
and circuits in sleep-deprived humans [17,40].
Because of the differential actions in DLPC and DStr versus
MTL, it is possible that CX717 inﬂuenced the attempts of
selective neural circuits to restore total brain activation to a
pattern exhibited under normal alert conditions. This would
seem logical if additional mechanisms were activated under
sleep deprivation conditions to compensate for decreased
performance of the task [15,18,40,43]. Reciprocal changes in
DPFC and MTL in the sleep deprivation versus sleep
deprivationþCX717 condition may reﬂect switching between
different brain activation patterns as indicated in Figure 9B.
In this regard, the fact that the drug-related regional CMRglc
pattern in sleep-deprived animals resembled the pattern in
these same regions observed under normal alert conditions
(see Figure 8) suggests that the action of CX717 was to revert
the brain to a state sufﬁcient to perform the task successfully.
The functional linkage between brain regions engaged by
the DMS task and their susceptibility to sleep deprivation and
CX717 was demonstrated by the multivariate CDA analysis
(Figure 9), which showed that brain metabolic changes (see
Figures 7F–7H and 8A–8C) and behavioral performance
(see Figures 2 and 4) in each test condition covaried within
individual animals [17]. Three independent sources of
variance were extracted from the covariance matrix, and
each was determined to result from a major manipulation in
the study; DMS task parameters (DF1), presence of CX717
(DF2), and exposure to 30–36 h of sleep deprivation (DF3).
The CDA revealed that DF2 and DF3 were additive within
individual animals and present when performance (DF1) was
reversed in the sleep deprivation þ CX717 condition (Figure
9A). This conﬁrmed that the differential alterations in CMRglc
in speciﬁc brain regions by sleep deprivation (DPFC, DStr,
and MTL; Figure 8) were speciﬁc to CX717 action in sleep-
deprived animals (Figure 9B), suggesting that these areas were
linked with respect to susceptibility to sleep deprivation and
CX717 effects [17,44].
Although the ﬁnding that separate brain regions (DPFC,
DStr, and MTL) were differentially altered by sleep depriva-
tion (see Figure 8) is consistent with several human studies
[15,16,45], recent reports indicate that generalization of such
deﬁcits to other circumstances and tasks is not straightfor-
ward [18,19,43,44]. The demands of sleep deprivation most
likely engage different processes depending on both the type
and the difﬁculty of the task [17,40,44]. It has been suggested
that (1) different brain ‘‘circuits’’ may be activated under
sleep deprivation conditions that are not engaged under
normal conditions when performing the same tasks [17,44],
and (2) that such demands are expressed differently depend-
ing on the speciﬁc regions that are ‘‘recruited’’ to perform
the task [40,45]. At this time it is not possible to know whether
such factors are similarly expressed with respect to sleep
deprivation in nonhuman primates. The differential nature
of the disruption in CMRglc across different brain regions
shown here, however, suggests that compensatory processes
may have been involved.
The one brain area in which the effects of sleep deprivation
were not ameliorated by CX717 was the thalamus, which
showed very different CMRglc patterns in all conditions
compared to DPFC, DStr, precuneate cortex, and MTL
(Figure 9B). While CMRglc in the thalamus has been reported
to be affected in sleep deprivation [17,44] other reports using
functional magnetic resonance imaging actually found
increased thalamic activation in sleep-deprived humans
[15,40]. The lack of responsiveness to CX717 under either
normal or sleep deprivation conditions in the present study
(Figure 9B), however, provides new information regarding
mechanisms of sleep regulation by the thalamus. The
thalamic reticular nucleus, a major synchronizing inﬂuence
on cortical EEG, contains clusters of electrically coupled
neurons [46], which may not be directly affected by an AMPA
receptor modulator such as CX717. This lack of direct
synaptic inﬂuence could explain the sustained decrease in
thalamic CMRglc in the sleep deprivationþCX717 condition,
and perhaps also why the associated behavioral performance
(see Figure 4B) did not reverse to levels exhibited in the
normal þ CX717 condition (see Figure 2B).
Several investigations have shown that sleep deprivation
down-regulates glutamatergic as well as other synaptic and
receptor-mediated events in cortical neurons [47–50]. Ampa-
kines modify ionic current through glutamate-gated channels
with differential effectiveness across AMPA receptor sub-
types, primarily by modulating desensitization and slowing
channel closing [3–5,9,51]. The involvement in sleep and
wakefulness of glutamatergic synapses along with several
other neurotransmitter systems has been addressed in several
studies [52]. AMPA receptor stimulation in the nucleus basalis
of Meynert has been implicated in the activation of inhibitory
projections from this nucleus to other brain regions as the
basis for decreasing a particular type of sleep pattern [53].
Functional AMPA receptors have been shown in most of the
affected brain regions described here [14]; hence, their
enhancement by an agent such as CX717 could compensate
for down-regulated glutamatergic systems in sleep-deprived
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volved in sleep-waking cycles is orexin, a peptide that
prevents sleep in narcoleptic dogs and has also been shown
to release glutamate [52]. Consequently, the sleep-preventing
effects of orexin may be potentiated by CX717. Ampakines,
therefore, have the capability to positively modulate many
different glutamatergic circuits and pathways in several
pertinent brain regions [11], thereby increasing the potential
to counteract cognitive deﬁcits under normal as well as sleep
deprivation conditions [16,55–57].
Other compounds that have been utilized to combat the
effects of sleep deprivation, including psychostimulants
(amphetamine), caffeine, and modaﬁnil [58–62] act through
different, non-AMPA receptor-mediated, cell signaling path-
ways. The usefulness of these agents, however, may be limited
due to their potential for addiction and/or their potent
stimulant actions, which can distort cognitive and sensory
processes at doses required to counteract the effects of sleep
deprivation [58–62].
In this investigation, thea m p a k i n eC X 7 1 7i m p r o v e d
performance under both normal and sleep deprivation
conditions in a nonhuman primate model. The effects on
performance were accompanied by signiﬁcant changes in
local glucose metabolism in brain regions implicated in this
type of cognitive processing. Selective activation of these
brain regions over others during performance of the task,
and reciprocal modulation by CX717 versus sleep depriva-
tion, are key supportive outcomes of this study. The fact that
ampakines such as CX717 can temporarily alleviate the
effects of prolonged periods of sleep deprivation, even to
the extent of improving performance above normal levels,
indicates their potential applicability to many circumstances
in which human performance is compromised by extensive
sleep loss.
Materials and Methods
Subjects. All procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of Wake Forest
University, and performed in accordance with established practices
as described in the National Institutes of Health Guide for Care and
Use of Laboratory Animals. In this study, 11 adult male rhesus
monkeys (Macaca mulatta) weighing (8.0–11.0 kg) were utilized. They
were individually housed in stainless steel cages in temperature- and
humidity-controlled colony rooms with lighting maintained on a
0600:1800 on:off schedule, and were fed a diet of monkey chow
supplemented by fresh fruit to maintain daily-monitored body
weight. Fluid intake was restricted in time and amount such that a
large volume of an animal’s required daily ﬂuid intake (80 ml/kg) was
received either during the behavioral testing session, or within 2 h of
being returned to the home cage.
Behavioral testing. The number of sessions analyzed per condition
(normal vehicle, normal þ CX717, sleep deprivation, sleep depriva-
tion þ CX717) was 11–16, with nine monkeys tested at least once per
condition, and two additional monkeys tested only under normal
vehicle and normal þ CX717 conditions. Animals were placed in a
primate chair 1.5 m in front of an LCD-front-projection screen for
daily testing on a visual DMS task [24] and performed 150–300 trials
per session. Animals were trained to move a cursor tracked by a
ﬂuorescent marker attached to the back of the monkey’s hand into
the images by positioning the hand within a two-dimensional
coordinate system referenced to an extended armrest on the chair.
Stimuli consisted of clip art images projected as 25-cm squares within
a33 3 position matrix onto a 1.0 m 3 1.0 m display. Responses to
appropriate stimuli were rewarded with 0.5 ml of diluted fruit juice.
Restricting most ﬂuid intake to the task or 2 h after task completion
ensured that animals were motivated to work for the liquid
reinforcement. All animals were trained to a stable baseline on the
DMS task in which delay varied randomly from 1 s to 30 s on a given
trial, and the number of nonmatch stimuli (images) varied randomly
from two to six in the match phase of the task (see Figure 1).
Performance accuracy varied directly with duration of delay and
number of nonmatch images (number of images) presented in the
match phase. An individual image was used on only one trial per day,
and the sets of images were routinely changed to maintain the trial-
unique feature of each session.
Sleep deprivation procedure. Sleep deprivation consisted of 30–36
h of continuous sleep prevention supervised by laboratory personnel.
Animals were maintained in a cage separate from their home cages in
a continuously lighted room and kept awake with videos, music,
occasional treats, gentle cage shaking, and interaction with techni-
cians until their usual daily testing time. EEG recordings were
obtained in four animals from a set of ﬁve recording electrodes
consisting of 1 mm diameter Ag/AgCl pellets on silver wire placed on
the exposed dura around the circumference of a 1.5 cm diameter
craniotomy access cylinder positioned over the parietal cortex and
permanently attached to the skull. EEG was digitized at 200 Hz, and
low pass ﬁltered to 0.1–45 Hz. EEG was recorded during normal
vehicle, sleep deprivation, and sleep deprivation þ CX717 sessions,
for 10 min before testing, and throughout the DMS testing session.
Mean PSD was calculated from Fourier transforms of the EEG over
different time epochs. Determination of sleepiness was assessed by
the relative power of the EEG in terms of frequency bands: delta (0.5–
5 Hz), alpha (8–12 Hz), sigma (spindles, 12–15 Hz), and beta (15–25
Hz). Transitions in EEG frequency during testing sessions were
assessed by calculating PSDs in 4.0-s epochs over the entire session
[25,26], which allowed insight into the basis of individual peaks in
averaged PSD plots over longer time intervals (see Figure 6). Sleep
deprivation sessions were conducted a minimum of 10 d apart with
normal alert sessions interleaved to allow full recovery of baseline
performance levels (typically within 24–48 h) following the sleep
deprivation session.
Drug administration. The ampakine CX717 (Cortex Pharmaceut-
icals, Irvine, California, United States) was administered in 10% w/v
hydroxypropyl-beta-cyclodextrin and saline (0.45%) vehicle through
an intravenous vascular access port chronically implanted in each
monkey. CX717 was mixed as 1.5 mg/ml and administered within a
dose range of 0.3–1.5 mg/kg to each monkey (weight range 8–11 kg).
Vehicle injections (cyclodextrin and saline) were administered to all
monkeyspriortonondrugsessions.CX717invehiclewasadministered
10minpriortothestartofeachdrugsession.Normalsessionsinwhich
CX717 was administered were interposed between days with vehicle
(normal vehicle) sessions. Recovery of baseline DMS performance was
required prior to administration of CX717 in either sleep deprivation
or normal vehicle sessions. In sessions in which PET scans were
conducted, CX717 was administered 10 min prior to isotope injection.
Measurement of local rates of cerebral glucose metabolism.
Measurements of rates of cerebral glucose metabolism (CMRglc) were
made in nine of the 11 monkeys in ﬁve different conditions: (1)
baseline ‘‘no task’’ condition during which monkeys watched a video,
(2) DMS task/normal vehicle, (3) DMS task/normal þ CX717, (4) DMS
task/sleep deprivation, and (5) DMS task/sleep deprivation þ CX717.
Animals were scanned twice in the baseline, normal vehicle, and
normalþCX717 conditions. All animals (n¼9) were acclimated to the
PET scan procedures, including blood collection, during several
sessions prior to the initial scans in order to prevent disruption of
performance. On the day of the scan the monkeys were placed in
primate chairs and the DMS task initiated. Animals worked for ten
trials prior to receiving a 30 s injection of 3–5 mCi of [
18F]-2-deoxy-2-
ﬂuoro-D-glucose (FDG), after which they performed the DMS task for
a total of 40 min. Animals were fully awake and behaving at all times
during tracer uptake. Since the metabolized glucose tracer is taken
up and trapped in cells for a minimum of 90 min after incorporation,
measurement of the metabolized tracer reﬂected activation of brain
regions during 80–100 trials of behavioral performance in the task.
Following task completion, animals were anesthetized with ketamine
(15 mg/kg IV) and transported to the PET scanner. Anesthesia was
maintained by supplemental ketamine (10 mg/kg intramuscularly).
Following scan acquisition, monkeys were transported back to their
home cages and continuously monitored until fully recovered.
A total of three blood samples were collected from the femoral vein
(opposite the catheter): 10 min prior to tracer injection, and 8 min
and 42 min postinjection. Tracer concentrations were measured in
blood samples using an automated gamma well counter. A popula-
tion-averaged FDG blood curve (calculated for monkey) was scaled to
the measured blood curve for the time period from injection to the
end of the PET scan [63]. Data were transformed to CMRglc based on
the operational equation [64,65]. Rate constants (k1,k 2, and k3) and
lumped constant as determined in monkey by Kennedy et. al. [66],
along with a k4 value used in human studies [65] were applied.
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Systems, Milwaukee, Wisconsin, United States) Advance NXi PET
scanner with a resolution of 4 mm. Scanning consisted of a 5-min
transmission scan acquired in 2D mode, followed by a 10-min
emission scan acquired in 3D mode. The image reconstruction of the
3D data used the 3D-reprojection method with full quantitative
corrections. Transmission scan data were smoothed using a 4-mm
Gaussian ﬁlter transaxially and then segmented. The emission data
were corrected for attenuation and reconstructed into 128 3 128
matrices using a Hanning ﬁlter with a 4-mm cutoff transaxially, and a
ramp ﬁlter with an 8.5-mm cutoff axially.
PET data were analyzed with Statistical Parametric Mapping
(SPM99) software (University College London, London, United
Kingdom; http://www.ﬁl.ion.ucl.ac.uk/spm/) implemented in MATLAB
(MathWorks, Natick, Massachusetts, United States). Reconstructed
images for each scan from each of the nine monkeys were co-
registered to corresponding structural MR images obtained on a 1.5-
T MR scanner (GE Medical Systems) using automated image
registration [67] and then transformed spatially into a standard
space with an FDG template for rhesus monkeys constructed in our
laboratory based on procedures of Black and colleagues [68].
Resultant images were smoothed using a 2 mm isotropic Gaussian
kernel with a voxel size of 1 mm 3 1m m3 1 mm. Scans were
normalized for differences in global activity by proportional scaling.
Effects at each voxel were estimated according to the general linear
model using the multi-subject conditions and covariates option in
SPM99 software. Statistical parametric maps were created for the
following comparisons: normal vehicle versus baseline (no task);
normal þ CX717 versus normal vehicle; sleep deprivation versus
normal vehicle; and sleep deprivation versus sleep deprivation þ
CX717.Exploratoryanalysesusedaminimumvoxelheight(magnitude)
threshold of p , 0.01 and a minimum cluster size of 50 voxels. A region
of interest analysis was conducted including DPFC, MTL, parietal
cortex (precuneus), thalamus, and DStr, selected based on previous
imaging reports in nonhuman primates implicating these regions in
delay and working memory tasks [37,38]. Spherical ROIs were
constructed on a structural MR template using the MarsBaR toolbox
contained in SPM99. Statistical signiﬁcance for the four comparisons
described above was determined with a threshold value of p , 0.05
corrected for the search volume. Areas of activation were displayed on
aT 1 weighted anatomic MRI template [68]. Regions were then
identiﬁed with reference to standard atlases of the primate brain [69].
Further analyses were conducted on the PET data for use with
multivariate analyses. Each of the PET datasets as described above was
co-registered to structural MR images, and a template of ROIs
created on the MR image. ROIs were chosen on the basis of the results
of the SPM analysis and included the same ﬁve brain areas listed
above: DPFC, parietal cortex, DStr, thalamus, MTL, plus cingulate
cortex. Absolute rates of CMRglc were determined bilaterally for each
animal for each condition. These data were used for the multivariate
canonical discriminant analysis.
Multivariate analysis of performance and brain glucose utilization.
To conclusively demonstrate that measures of DMS performance and
CMRglc covaried within animals across the four test conditions
(normal vehicle, normal þ CX717, sleep deprivation, and sleep
deprivation þ CX717), a multivariate CDA [70] was performed. The
CDA extracted common sources of variance from a covariance matrix
that included all relevant dimensions of the study [32], including
measures of behavioral performance and CMRglc from individual
sessions in nine different monkeys. There were six behavioral
measures: (1) percent correct over all trials, (2) percent correct on
the most difﬁcult trials (21–30 s delays and 5–6 images), (3) percent
correct on the least difﬁcult trials (1–10 s delays and 2–3 images), (4)
response latency to start the trial, (5) latency to sample response, and
(6) latency to match response. The other six measures consisted of
absolute levels of CMRglc from six different brain regions: (7) DPFC,
(8) DStr, (9) MTL, (10) thalamus, (11) precuneus, and (12) cingulate
cortex, determined by separate ROIs computed speciﬁcally for the
CDA. All 12 of the above measures were determined for each of nine
monkeys under the four different test conditions.
The CDA program (PROC CANDISC, SAS Institute, Cary, North
Carolina, United States) constructed canonical covariance matrices
between dependent variables (behavioral and CMRglc measures)
across each of the four conditions, then performed an eigenvector
decomposition (‘‘factoring’’) to produce normalized, orthogonal DFs
such that:
Xn,p ¼ Dn,j   Wj,p þ En,p (1)
Where n ¼ number of observations, p ¼ number of dependent
variables, j¼number of eigenvectors (extracted by the CDA), X is the
matrix of raw data, D is the matrix of discriminant scores, W is the
matrix of eigenvectors (i.e., coefﬁcients of the DFs), E is the matrix of
residual error, and   indicates the matrix dot-product. DF scores for
each monkey and condition were computed from the coefﬁcients via
the formula:
Xn,p   W9p,j ¼ Dn,j (2)
Where X comprises the raw data matrix, with n, p, and j indices as
described above, W9 is the inverse of the eigenvector coefﬁcient
matrix, and D is the matrix of discriminant scores. The eigenvectors
were orthogonally rotated to (1) distribute scores around a mean of
zero, with standard deviation of one, and (2) maximize the
Mahalonobis distances between measures within treatment condi-
tions. With n ¼ 36 (9 monkeys 3 4 conditions), p ¼ 12 (dependent
variables), and j¼3 (DFs), 108 discriminant scores were produced and
tested by two-way ANOVA for differences between the four test
conditions. Variance contribution for each DF from the matrix of
eigenvalues (V, produced concomitantly with the eigenvector
decomposition) was compared with the sum (v) of all eigenvalues
and residual error (E, above) to derive the proportion of total
variance accounted for by each DF [70].
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